Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$57.96

-1.25 (-2.11%)

, GILD

Gilead

$74.46

-0.52 (-0.69%)

16:03
11/22/16
11/22
16:03
11/22/16
16:03

Galapagos reports 1st patient dosing in DIVERSITY Phase 3 study

Galapagos (GLPG) reports the first dosing of a patient in the DIVERSITY Phase 3 study with filgotinib in Crohn's disease (CD). The start of the DIVERSITY study triggers a $50 million milestone payment from Gilead (GILD) The worldwide DIVERSITY Phase 3 study will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily compared to placebo in 1,320 patients with moderately to severely active Crohn's disease, including those with prior biological therapy failure. "With the FITZROY Phase 2 study, Galapagos demonstrated that filgotinib has a promising efficacy and safety profile in Crohn's disease. The start of the Phase 3 DIVERSITY study is good news for patients with Crohn's disease," said Dr Piet Wigerinck, CSO of Galapagos. "We look forward to seeing the results of DIVERSITY."Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. In addition to the DIVERSITY study, Gilead initiated the FINCH Phase 3 program in rheumatoid arthritis in August 2016 and is expected to start the SELECTION Phase 2b/3 study in ulcerative colitis later this quarter. Filgotinib is an investigational drug and its efficacy and safety have not been established.

GLPG

Galapagos NV

$57.96

-1.25 (-2.11%)

GILD

Gilead

$74.46

-0.52 (-0.69%)

  • 29

    Nov

  • 30

    Nov

  • 14

    Dec

GLPG Galapagos NV
$57.96

-1.25 (-2.11%)

10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.
10/18/16
GSCO
10/18/16
UPGRADE
GSCO
Buy
Galapagos NV upgraded to Buy from Neutral at Goldman
10/27/16
JEFF
10/27/16
NO CHANGE
Target $102
JEFF
Buy
Jefferies sees Galapagos as reducing competitive concerns for Vertex
Jefferies analyst Brian Abrahams believes the "difficult to interpret" data from Galapagos (GLPG) should help reduce the "overdone" competitive concerns weighing on shares of Vertex Pharmaceuticals (VRTX). Galapagos' data for GLPG1837 show "possible signals of activity, but short study, small sample size, underdosing, and variability makes the results very difficult to conclusively interpret," Abrahams tells investors in a research note. The North American Cystic Fibrosis Conference highlights the early stage of any potential competitor and Vertex's "significant developmental lead time," the analyst contends. He reiterates a Buy rating on the shares with a $102 price target.
11/01/16
WBLR
11/01/16
DOWNGRADE
Target $81
WBLR
Market Perform
William Blair downgrades Vertex with competition looming
William Blair analyst Y. Katherine Xu downgraded Vertex Pharmaceuticals (VRTX) to Market Perform from Outperform after attending the North American Cystic Fibrosis Conference. Looming competition "has become more and more real," Xu tells investors in a research note. The triple combo in vitro data from Vertex, AbbVie (ABBV)/Galapagos (GLPG) and Proteostasis (PTI) appear comparable, Xu contends. The analyst expects "deteriorating pricing" for the Vertex's Cystic Fibrosis franchise starting in 2022 due to competition. She lowered her price target for the shares to $81 from $105. Vertex closed yesterday at $78.86.
GILD Gilead
$74.46

-0.52 (-0.69%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $89
LEER
Market Perform
Gilead myelofibrosis data miss may open path for M&A, says Leerink
Leerink analyst Geoffrey Porges notes that Gilead (GILD) released disappointing Phase III data for its JAK 1/2 inhibitor momelotinib in myelofibrosis. The company indicated that they plan to discuss these results with regulatory authorities to determine the next steps, but it seems likely that momelotinib will be written off, he adds. However, Porges believes that this disappointment restores Incyte (INCY) to the list of feasible candidates for acquisition by Gilead, since it would no longer face the obligation to divest one of the overlapping JAK programs. He reiterates a Market Perform rating and $89 price target on Gilead's shares.
11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

CACI

CACI

$120.85

0.85 (0.71%)

08:12
06/22/17
06/22
08:12
06/22/17
08:12
Hot Stocks
CACI sees September quarter 'particularly strong in awards, funding' »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

ZGNX

Zogenix

$15.00

0.25 (1.69%)

08:12
06/22/17
06/22
08:12
06/22/17
08:12
Hot Stocks
Zogenix receives ODD from FDA for ZX008 »

Zogenix announced the FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$13.79

0.05 (0.36%)

08:12
06/22/17
06/22
08:12
06/22/17
08:12
Downgrade
Celestica rating change  »

Celestica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$37.23

-0.92 (-2.41%)

08:11
06/22/17
06/22
08:11
06/22/17
08:11
Hot Stocks
Nielsen and Trax partner to develop shelf consumer data solution »

Nielsen and Trax, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUNW

Sunworks

$1.56

0.0315 (2.06%)

08:11
06/22/17
06/22
08:11
06/22/17
08:11
Hot Stocks
Sunworks announces new project for 760 KW solar system in Nevada »

Sunworks announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVEE

NV5 Global

$41.45

-0.5 (-1.19%)

08:10
06/22/17
06/22
08:10
06/22/17
08:10
Hot Stocks
NV5 Global awarded $7M contract for Bridge Replacement »

NV5 Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$28.55

0.03 (0.11%)

08:09
06/22/17
06/22
08:09
06/22/17
08:09
Periodicals
Vodafone incorrectly charged 'Red Roaming' customers, Independent says »

Vodafone may face action…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$13.87

0.14 (1.02%)

08:09
06/22/17
06/22
08:09
06/22/17
08:09
Initiation
Del Taco initiated  »

Del Taco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$48.43

0.4 (0.83%)

08:08
06/22/17
06/22
08:08
06/22/17
08:08
Technical Analysis
Technical View: American Airlines trades higher in pre-market »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

QGEN

QIAGEN

$34.83

0.08 (0.23%)

08:08
06/22/17
06/22
08:08
06/22/17
08:08
Hot Stocks
QIAGEN's QuantiFERON TB test reimbursement approved by French health system »

QIAGEN's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.43

0.4 (0.83%)

08:08
06/22/17
06/22
08:08
06/22/17
08:08
Hot Stocks
Breaking Hot Stocks news story on American Airlines »

American Airlines:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

SNE

Sony

$38.14

-0.02 (-0.05%)

, WWE

WWE

$20.38

0.23 (1.14%)

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Hot Stocks
Sony Pictures Networks India, WWE announce WWE Sunday Dhamaal »

Sony Pictures Networks…

SNE

Sony

$38.14

-0.02 (-0.05%)

WWE

WWE

$20.38

0.23 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.43

0.4 (0.83%)

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Hot Stocks
Breaking Hot Stocks news story on American Airlines »

American Airlines:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

GTIM

Good Times Restaurants

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Initiation
Good Times Restaurants initiated  »

Good Times Restaurants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$48.43

0.4 (0.83%)

08:07
06/22/17
06/22
08:07
06/22/17
08:07
Hot Stocks
Breaking Hot Stocks news story on American Airlines »

American Airlines: Qatar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

KMX

CarMax

$59.74

0.48 (0.81%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Downgrade
CarMax rating change  »

CarMax downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 30

    Jun

AAL

American Airlines

$48.43

0.4 (0.83%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Hot Stocks
American Airlines: Qatar Airways intends to make 'significant' investment »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 07

    Jul

ANF

Abercrombie & Fitch

$12.05

-0.16 (-1.31%)

08:06
06/22/17
06/22
08:06
06/22/17
08:06
Upgrade
Abercrombie & Fitch rating change  »

Correction: Abercrombie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
06/22/17
06/22
08:05
06/22/17
08:05
General news
Treasury Market Outlook: bonds are little changed »

Treasury Market Outlook:…

WFM

Whole Foods

$43.26

0.48 (1.12%)

, KR

Kroger

$22.37

-0.01 (-0.04%)

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Recommendations
Whole Foods, Kroger, Costco, Target, Wal-Mart, Amazon.com analyst commentary  »

JPMorgan has 'hard…

WFM

Whole Foods

$43.26

0.48 (1.12%)

KR

Kroger

$22.37

-0.01 (-0.04%)

COST

Costco

$163.15

0.25 (0.15%)

TGT

Target

$50.52

-0.39 (-0.77%)

WMT

Wal-Mart

$76.24

0.7 (0.93%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 28

    Jun

  • 23

    Aug

ISBC

Investors Bancorp

$13.08

-0.18 (-1.36%)

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
Investors Bancorp appoints Michael Fegan Chief Information and Operations Office »

Investors Bank has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JW.A

John Wiley

$51.75

0.4 (0.78%)

, JW.B

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
John Wiley & Sons raises quarterly dividend 3% to 32c per share »

John Wiley & Sons…

JW.A

John Wiley

$51.75

0.4 (0.78%)

JW.B

JWB

John Wiley & Sons; also tag JWA

JWA

John Wiley & Sons; also tag JWB

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AME

Ametek

$60.51

-1.36 (-2.20%)

, MOCO

Mocon

08:04
06/22/17
06/22
08:04
06/22/17
08:04
Hot Stocks
Ametek completes acquisition of Mocon »

Ametek (AME) announced…

AME

Ametek

$60.51

-1.36 (-2.20%)

MOCO

Mocon

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$65.05

-0.5 (-0.76%)

08:03
06/22/17
06/22
08:03
06/22/17
08:03
Hot Stocks
Trinseo increases quarterly dividend, announces new share repurchase program »

Trinseo announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.95

0.0471 (5.24%)

08:02
06/22/17
06/22
08:02
06/22/17
08:02
Hot Stocks
Trovagene to provide Trovera tests and services for global pharma company »

Trovagene has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.